WellSpring Pharmaceutical Corp. has expanded its consumer health care product line with the acquisition of several OTC products from McNeil Consumer Healthcare Division. In an all-cash transaction, WellSpring has purchased U.S. rights to Micatin (antifungal), Emetrol (anti-nausea), and Gelusil (antacid), and the Canadian rights to Micatin, Gelusil, and Glycerin Suppositories (laxative).  
   
In the U.S. the new brands give WellSpring a base in the consumer healthcare market where the company plans to launch its OTC skin care products, Glaxal Base and Barriere. The company also provides contract manufacturing services.
   
“With consumers taking more responsibility for their own health, this segment of the pharmaceutical market holds substantial promise for growth,” said Dr. Robert A. Vukovich, WellSpring’s president and chief executive officer. “Having marketed OTC products in Canada for many years, our experience in growing this pharmaceutical category should prove to be very beneficial. WellSpring expects to undertake an aggressive marketing effort to re-invigorate these products and expand their distribution,” Dr. Vukovich said.